GV, a venture capital firm, LYFE Capital, a healthcare focused private equity company, and Revelation Partners, a private equity firm, led a $148m Series B funding round in Aspen Neuroscience, a private biotechnology company developing autologous cell therapies, with participation from Newton Investment, EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment, OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Section32 and Alexandria Venture Investments. "This company was founded by a visionary team of scientists and patient advocates, who envisioned a day when personalized cell replacement could be used to target neurodegenerative diseases. We are happy to be aligned with such a prestigious group of founders and investors, having raised more than $220 million since the company's founding, towards our mission to develop transformational medicines for patients with limited treatment options," Damien McDevitt, Aspen Neuroscience President and CEO.